2026 Q1 -tulosraportti
25 päivää sitten
‧43 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 92 | NON | NON | ||
| 287 | DDB | NON | ||
| 500 | NON | NON | ||
| 108 | NON | NON | ||
| 605 | NON | NON |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 27.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 29.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·1 t sittenWhy should the share price fall, 20 million more has come into the company, i.e. the company is strengthened/stands stronger. I only see a fall if the new shareholders want to sell the shares they just bought. The share price only falls, I suppose, if more want to sell than buy... So why should it fall? Do you think the new major shareholders will already sell their shares?
·2 t sitten · MuokattuExciting PM this evening! Curasight raises DKK 20 mio. with a dilution of just 2.27 % and simultaneously extends the Fenja loan until June 2027. The interesting thing is what the money will be used for: • FDA IND application in GBM • Preparation of phase 1b/2 or expansion cohorts • Next-generation peptide for the basket study This is happening mind you BEFORE we have received the final uTREAT phase I topline results - that looks really good now! At the same time, there are still no: • new studies announced in H2 2026 • signs that they are building a large independent organization It doesn't look like a company under pressure. It rather looks like a company buying itself time and opportunities towards the next crucial data point(s). If the plan is to finance larger phase II programs alone, why are they only raising DKK 20 mio.? And how does that align with Ulrich's previous statements that new studies must have an agreement behind them? In my opinion, this fits with a sale (or a partnership agreement) being on the way.
·7 t sittenExciting with a directed share issue tonight. I guess a price of 19.50-20.00 and then that uncertainty about capital (increase) is laid to rest for a good while. That the price has been quite solid at 21-22 for the last 10 days now makes very good sense....
It is true that they will stand much stronger in future negotiations and the longer they can manage on their own, the more expensive they will be to acquire. Exciting!
7 t sitten · Muokattu——Curasight A/S announces its intention to carry out a directed issue of shares—- Curasight A/S ("Curasight" or the "Company" – TICKER: CURAS) hereby announces its intention to carry out a directed issue of shares of a minimum of approximately DKK 18 million through an accelerated book-building procedure (the “Directed Issue”). Curasight recently reported encouraging interim data from its Phase I uTREAT® study. Following these results, the Company intends to carry out the Directed Issue intended to strengthen its working capital and support the continued clinical development of uTRACE® and uTREAT® through the end of H1 2027. In connection with the Directed Issue, the Company also intends to renegotiate the outstanding loan from Fenja Capital II A/S ("Fenja Capital", the "Lender"). https://news.cision.com/curasight/r/curasight-a-s-announces-its-intention-to-carry-out-a-directed-issue-of-shares,c4366350Yes, one must certainly hope for that. With what they are proposing, it should not go below 22.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
25 päivää sitten
‧43 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 t sittenWhy should the share price fall, 20 million more has come into the company, i.e. the company is strengthened/stands stronger. I only see a fall if the new shareholders want to sell the shares they just bought. The share price only falls, I suppose, if more want to sell than buy... So why should it fall? Do you think the new major shareholders will already sell their shares?
- ·2 t sitten · MuokattuExciting PM this evening! Curasight raises DKK 20 mio. with a dilution of just 2.27 % and simultaneously extends the Fenja loan until June 2027. The interesting thing is what the money will be used for: • FDA IND application in GBM • Preparation of phase 1b/2 or expansion cohorts • Next-generation peptide for the basket study This is happening mind you BEFORE we have received the final uTREAT phase I topline results - that looks really good now! At the same time, there are still no: • new studies announced in H2 2026 • signs that they are building a large independent organization It doesn't look like a company under pressure. It rather looks like a company buying itself time and opportunities towards the next crucial data point(s). If the plan is to finance larger phase II programs alone, why are they only raising DKK 20 mio.? And how does that align with Ulrich's previous statements that new studies must have an agreement behind them? In my opinion, this fits with a sale (or a partnership agreement) being on the way.
- ·7 t sittenExciting with a directed share issue tonight. I guess a price of 19.50-20.00 and then that uncertainty about capital (increase) is laid to rest for a good while. That the price has been quite solid at 21-22 for the last 10 days now makes very good sense....It is true that they will stand much stronger in future negotiations and the longer they can manage on their own, the more expensive they will be to acquire. Exciting!
- 7 t sitten · Muokattu——Curasight A/S announces its intention to carry out a directed issue of shares—- Curasight A/S ("Curasight" or the "Company" – TICKER: CURAS) hereby announces its intention to carry out a directed issue of shares of a minimum of approximately DKK 18 million through an accelerated book-building procedure (the “Directed Issue”). Curasight recently reported encouraging interim data from its Phase I uTREAT® study. Following these results, the Company intends to carry out the Directed Issue intended to strengthen its working capital and support the continued clinical development of uTRACE® and uTREAT® through the end of H1 2027. In connection with the Directed Issue, the Company also intends to renegotiate the outstanding loan from Fenja Capital II A/S ("Fenja Capital", the "Lender"). https://news.cision.com/curasight/r/curasight-a-s-announces-its-intention-to-carry-out-a-directed-issue-of-shares,c4366350Yes, one must certainly hope for that. With what they are proposing, it should not go below 22.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 92 | NON | NON | ||
| 287 | DDB | NON | ||
| 500 | NON | NON | ||
| 108 | NON | NON | ||
| 605 | NON | NON |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 27.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 29.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 |
2026 Q1 -tulosraportti
25 päivää sitten
‧43 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 27.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 29.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 t sittenWhy should the share price fall, 20 million more has come into the company, i.e. the company is strengthened/stands stronger. I only see a fall if the new shareholders want to sell the shares they just bought. The share price only falls, I suppose, if more want to sell than buy... So why should it fall? Do you think the new major shareholders will already sell their shares?
- ·2 t sitten · MuokattuExciting PM this evening! Curasight raises DKK 20 mio. with a dilution of just 2.27 % and simultaneously extends the Fenja loan until June 2027. The interesting thing is what the money will be used for: • FDA IND application in GBM • Preparation of phase 1b/2 or expansion cohorts • Next-generation peptide for the basket study This is happening mind you BEFORE we have received the final uTREAT phase I topline results - that looks really good now! At the same time, there are still no: • new studies announced in H2 2026 • signs that they are building a large independent organization It doesn't look like a company under pressure. It rather looks like a company buying itself time and opportunities towards the next crucial data point(s). If the plan is to finance larger phase II programs alone, why are they only raising DKK 20 mio.? And how does that align with Ulrich's previous statements that new studies must have an agreement behind them? In my opinion, this fits with a sale (or a partnership agreement) being on the way.
- ·7 t sittenExciting with a directed share issue tonight. I guess a price of 19.50-20.00 and then that uncertainty about capital (increase) is laid to rest for a good while. That the price has been quite solid at 21-22 for the last 10 days now makes very good sense....It is true that they will stand much stronger in future negotiations and the longer they can manage on their own, the more expensive they will be to acquire. Exciting!
- 7 t sitten · Muokattu——Curasight A/S announces its intention to carry out a directed issue of shares—- Curasight A/S ("Curasight" or the "Company" – TICKER: CURAS) hereby announces its intention to carry out a directed issue of shares of a minimum of approximately DKK 18 million through an accelerated book-building procedure (the “Directed Issue”). Curasight recently reported encouraging interim data from its Phase I uTREAT® study. Following these results, the Company intends to carry out the Directed Issue intended to strengthen its working capital and support the continued clinical development of uTRACE® and uTREAT® through the end of H1 2027. In connection with the Directed Issue, the Company also intends to renegotiate the outstanding loan from Fenja Capital II A/S ("Fenja Capital", the "Lender"). https://news.cision.com/curasight/r/curasight-a-s-announces-its-intention-to-carry-out-a-directed-issue-of-shares,c4366350Yes, one must certainly hope for that. With what they are proposing, it should not go below 22.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 92 | NON | NON | ||
| 287 | DDB | NON | ||
| 500 | NON | NON | ||
| 108 | NON | NON | ||
| 605 | NON | NON |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt